Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global population that can lead to end-stage liver disease and hepatocellular carcinoma (HCC). NAFLD is closely linked to the metabolic syndrome, and comorbidities such as type 2 diabetes, obesity and insulin resistance aggravate liver disease, while NAFLD promotes cardiovascular risk in affected patients. The pathomechanisms of NAFLD are multifaceted, combining hepatic factors including lipotoxicity, mechanisms of cell death and liver inflammation with extrahepatic factors including metabolic disturbance and dysbiosis. Nuclear receptors (NRs) are a family of ligand-controlled transcription factors that regulate glucose, fat and cholesterol homeostasis and modulate innate immune cell functions, including liver macrophages. In parallel with metabolic derangement in NAFLD, altered NR signaling is frequently observed and might be involved in the pathogenesis. Therapeutically, clinical data indicate that single drug targets thus far have been insufficient for reaching patient-relevant endpoints. Therefore, combinatorial treatment strategies with multiple drug targets or drugs with multiple mechanisms of actions could possibly bring advantages, by providing a more holistic therapeutic approach. In this context, peroxisome proliferator-activated receptors (PPARs) and other NRs are of great interest as they are involved in wide-ranging and multi-organ activities associated with NASH progression or regression. In this review, we summarize recent advances in understanding the pathogenesis of NAFLD, focusing on mechanisms of cell death, immunometabolism and the role of NRs. We outline novel therapeutic strategies and discuss remaining challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metabolic processes in both hepatocytes and non-parenchymal liver cells are modulated by nuclear receptors”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–238 of 238
Bhattacharya, D., Basta, B., Mato, J. M., Craig, A., Fernández-Ramos, D., Lopitz-Otsoa, F., Tsvirkun, D., Hayardeny, L., Chandar, V., Schwartz, R. E., et al. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100237 · Cited by 75 · cited 1×
“Those beneficial effects were observed in several experimental models leading to further assessment in clinical studies [235,236].”
BackgroundHameed, B., Terrault, N. A., Gill, R. M., Loomba, R., Chalasani, N., Hoofnagle, J. H., Van Natta, M. L., & CRN, F. T. N. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14492 · Cited by 73 · cited 1×
“However, the authors observed increasing levels of alkaline phosphatase (ALP), low-density lipoprotein-C (LDL-C) and hemoglobin A1c levels (HbA1c) compared to placebo groups [232].”
BackgroundPeiseler, M., & Tacke, F. (2021) · Cancers · doi:10.3390/cancers13040730 · Cited by 71 · cited 1×
“In NASH, leaky gut leads to KCs and macrophages exposure to bacteria and endotoxins [113].”
BackgroundSelf-citationCyclophilin D deficiency attenuates mitochondrial perturbation and ameliorates hepatic steatosis
Wang, X., Du, H., Shao, S., Bo, T., Yu, C., Chen, W., Zhao, L., Li, Q., Wang, L., Liu, X., et al. (2018) · Hepatology · doi:10.1002/hep.29788 · Cited by 70
Macrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism
Krenkel, O., & Tacke, F. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1604480 · Cited by 66
Self-citationCurrent and emerging pharmacotherapeutic interventions for the treatment of liver fibrosis
Lambrecht, J., van Grunsven, L. A., & Tacke, F. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1774553 · Cited by 64 · cited 1×
“As awareness of NAFLD is increasing globally [206], ongoing preclinical and clinical studies provided various pathomechanistic insights into disease development and progression, identifying many new potential drug targets [24,207,208].”
BackgroundSelf-citationAbdelmalek, M. F., Charles, E. D., Sanyal, A. J., Harrison, S. A., Neuschwander-Tetri, B. A., Goodman, Z., Ehman, R. A., Karsdal, M., Nakajima, A., Du, S., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106335 · Cited by 64 · cited 2×
“gov (accessed on 28 December 2021) Identifier NCT03486912) [230].”
BackgroundMiranda, D. A., Krause, W. C., Cazenave-Gassiot, A., Suzawa, M., Escusa, H., Foo, J. C., Shihadih, D. S., Stahl, A., Fitch, M., Nyangau, E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96151 · Cited by 63 · cited 9×
“In addition, in NAFLD mouse models and patients, the aggregation of OSBPL3-related inflammation and fibrogenesis indicates that the LRH-1-OSBPL3 signal may trigger the pathogenesis of NASH [201,203,204].”
BackgroundInfluentialRogowski, M. P., Flowers, M. T., Stamatikos, A., Ntambi, J. M., & Paton, C. M. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m035865 · Cited by 60 · cited 1×
“The activation of SCD1 eventually favors the liver protection via a positive feedback regulation [140,141].”
BackgroundNi, M., Zhang, B., Zhao, J., Feng, Q., Peng, J., Hu, Y., & Zhao, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108778 · Cited by 60 · cited 1×
“In a NAFLD mouse model, LXR activation prohibited the cascade of phosphoinosine-3-kinase (PI3K), reducing TNFα expression and liver damage [191,192].”
BackgroundBile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications
Álvarez‐Sola, G., Uriarte, I., Latasa, M. U., Jiménez, M., Bárcena‐Varela, M., Santamaría, E., Urtasun, R., Rodríguez‐Ortigosa, C. M., Prìeto, J., Berraondo, P., et al. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.025 · Cited by 59 · cited 1×
“Potentially, FXR-FGF-15/-19 regulation favors liver regeneration after injury [165].”
BackgroundDynamic plasticity of macrophage functions in diseased liver
Ritz, T., Krenkel, O., & Tacke, F. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.007 · Cited by 58 · cited 1×
“Translational and clinical studies supplanted the former paradigms of “pro- and anti-inflammatory M1/M2 macrophages”, by revealing a tremendous heterogeneity among macrophage subsets and highlighting their functional plasticity [15].”
ResultSelf-citationBöhm, T., Berger, H., Nejabat, M., Riegler, T., Kellner, F., Kuttke, M., Sagmeister, S., Bazanella, M., Stolze, K., Daryabeigi, A., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.025 · Cited by 55 · cited 16×
“Dying hepatocytes release DAMPs, which activate pattern recognition receptors (PRRs) on KCs and induce the recruitment of immune cells (such as monocytes and neutrophils), thereby enhancing inflammation [112].”
BackgroundInfluentialSuzawa, M., Miranda, D. A., Ramos, K. A., Ang, K. K.-H., Faivre, E. J., Wilson, C. G. M., Caboni, L., Arkin, M. R., Kim, Y.-S., Fletterick, R. J., et al. (2015) · eLife · doi:10.7554/elife.09003 · Cited by 52 · cited 1×
“In addition, in NAFLD mouse models and patients, the aggregation of OSBPL3-related inflammation and fibrogenesis indicates that the LRH-1-OSBPL3 signal may trigger the pathogenesis of NASH [201,203,204].”
BackgroundQin, X., Wang, W., Wu, H., Liu, D., Wang, R., Xu, J., Jiang, H., & Pan, F. (2020) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2020.104674 · Cited by 47
Biological mechanisms and therapeutic relevance of the gasdermin family
Xia, S. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100890 · Cited by 46 · cited 1×
“GSDMs are activated by pro-inflammatory effectors, such as caspase-1, caspase-4/-5 and caspase-11, which exert their effector functions by cleaving GSDM proteins [62].”
BackgroundEmerging functions of the nuclear receptor LRH-1 in liver physiology and pathology
Sun, Y., Demagny, H., & Schoonjans, K. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166145 · Cited by 46 · cited 2×
“In addition, in NAFLD mouse models and patients, the aggregation of OSBPL3-related inflammation and fibrogenesis indicates that the LRH-1-OSBPL3 signal may trigger the pathogenesis of NASH [201,203,204].”
BackgroundSahini, N., & Borlak, J. T. (2016) · Translational research · doi:10.1016/j.trsl.2016.06.003 · Cited by 45 · cited 1×
“Furthermore, RNA-seq data from NAFLD or NASH patients showed that LRH-1 was significantly downregulated [205].”
Yang, F., Shang, L., Wang, S., Liu, Y., Ren, H., Zhu, W., & Shi, X. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2301903 · Cited by 45
The role of macrophages in obesity-driven chronic liver disease
Devisscher, L., Verhelst, X., Colle, I., Van Vlierberghe, H., & Geerts, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ru0116-016r · Cited by 44
Nuclear receptors and transcriptional regulation in non-alcoholic fatty liver disease
Xiao, Y., Kim, M., & Lazar, M. A. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101119 · Cited by 43
Beyond the Foam Cell: The Role of LXRs in Preventing Atherogenesis
Rasheed, A., & Cummins, C. L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082307 · Cited by 40 · cited 1×
“LXR deficiency of mice favors liver fibrogenesis and lipid accumulation [198,199].”
BackgroundRegulation of Hepatic Inflammation via Macrophage Cell Death
Li, Z., & Weinman, S. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1670674 · Cited by 40 · cited 1×
“Interestingly, free cholesterol is elevated in NASH livers in both humans and mice and has been proposed to be a lipotoxic DAMP, inducing NLRP3 activation and pyroptosis in Kupffer cells [40,74,75].”
BackgroundKaminsky-Kolesnikov, Y., Rauchbach, E., Abu-Halaka, D., Hahn, M., García-Ruiz, C., Fernandez-Checa, J. C., Madar, Z., & Tirosh, O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5393761 · Cited by 39
Ritchie, M., Hanouneh, I. A., Noureddin, M., Rolph, T., & Alkhouri, N. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1718104 · Cited by 36
Shi, C., Yang, H., & Zhang, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00139 · Cited by 36
Liu, Y., Han, X., Bian, Z., Peng, Y., You, Z., Wang, Q., Chen, X., Qiu, D., & Ma, X. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1902-9 · Cited by 35 · cited 1×
“In a NAFLD mouse model, LXR activation prohibited the cascade of phosphoinosine-3-kinase (PI3K), reducing TNFα expression and liver damage [191,192].”
BackgroundKamm, D. R., Pyles, K. D., Sharpe, M. C., Healy, L. N., Colca, J. R., & McCommis, K. S. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100807 · Cited by 34
ASC, IL-18 and Galectin-3 as Biomarkers of Non-Alcoholic Steatohepatitis: A Proof of Concept Study
Cyr, B. S., Keane, R. W., & Vaccari, J. P. D. R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228580 · Cited by 32 · cited 1×
“Hence, IL-18 tends to prevent tissue damage from overreactive immune responses [72,73].”
BackgroundSaroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue
Kumar, D., Goand, U. K., Gupta, S., Shankar, K., Varshney, S., Rajan, S., Srivastava, A., Gupta, A., Vishwakarma, A. L., Srivastava, A. K., et al. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.01.002 · Cited by 30 · cited 1×
“Further preclinical data confirmed those findings, also indicating beneficial effects on obesity, dyslipidaemia and insulin resistance in independent mouse models [215,216].”
BackgroundNew drugs for non‐alcoholic steatohepatitis
Cardoso, A., de Figueiredo‐Mendes, C., A. Villela‐Nogueira, C., & Sanyal, A. J. (2020) · Liver International · doi:10.1111/liv.14354 · Cited by 29 · cited 1×
“Although basic and translational research have identified many potential drug targets, approved pharmacological compounds for the treatment of NASH and fibrosis are still lacking, reducing current treatment strategies to difficult-to-sustain weight loss and lifestyle changes or to managing comorbidities such as optimi…”
BackgroundEndo-Umeda, K., Nakashima, H., Umeda, N., Seki, S., & Makishima, M. (2018) · Endocrinology · doi:10.1210/en.2017-03141 · Cited by 28
Bardová, K., Funda, J., Pohl, R., Čajka, T., Hensler, M., Kuda, O., Janovská, P., Adamcová, K., Irodenko, I., Lenkova, L., et al. (2020) · Nutrients · doi:10.3390/nu12123737 · Cited by 26 · cited 1×
“Combination of MSDC-0602K and Omega-3 fatty acids showed additive effects on triacylglycerol and fatty acid cycling in adipose tissue [218] in an obesity mouse model while combination with the glucagon-like peptide-1 receptor agonist liraglutide improved glucose tolerance and histologic features of NASH better than th…”
BackgroundLan, Q., Ren, Z., Chen, Y., Cui, G., Choi, I. C., Ung, C. O. L., Yu, H. H., & Lee, S. M. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00434-1 · Cited by 25 · cited 1×
“PPAR γ binding to p65 attenuated the production of inflammatory cytokines and chemokines driven by NF-κB in the liver [156].”
BackgroundThe expanding role of the bile acid receptor FXR in the small intestine
Cariou, B., & Staels, B. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.03.006 · Cited by 18
Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
Finan, B., Parlee, S. D., & Yang, B. S. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101153 · Cited by 17 · cited 1×
“Farnesoid X receptor (FXR) is the most important NR for the maintenance of bile acid (BA) synthesis [162,163].”
BackgroundRoles of nuclear receptors in hepatic stellate cells
Pu, S., Zhou, H., Liu, Y., Liu, J., Guo, Y., & Zhou, H. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1949288 · Cited by 13 · cited 15×
“In addition, the activation of hepatic stellate cells (HSCs) as the main collagen-producing myofibroblast population promoting liver fibrosis, is also influenced by NRs [23].”
BackgroundInfluentialYin, L., Busch, D. A., Qiao, Z., van Griensven, M., Teuben, M. P. J., Hildebrand, F., Pape, H., & Pfeifer, R. (2017) · Cytokine · doi:10.1016/j.cyto.2017.09.021 · Cited by 6
Cited by
Hepatic inflammatory responses in liver fibrosis
Hammerich, L., & Tacke, F. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00807-x · Cited by 803
Self-citationPeiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Self-citationMetabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Self-citationAn integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Self-citationKamata, S., Honda, A., & Ishii, I. (2023) · Biomolecules · doi:10.3390/biom13081264 · Cited by 81
Metadata
- Authors
- Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M.
- Affiliations
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Corresponding author
- Tacke, Frank
- Peiseler, Moritz
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-02-28
- Volume
- 23
- Issue
- 5
- Pages
- 2668
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8910763
- OpenAlex
- W4214523533
- Cited by
- 95
- References
- 238
- Citations by year
- 2026: 10 · 2025: 15 · 2024: 30 · 2023: 22 · 2022: 18
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Deutsche Forschungsgemeinschaft (SFB/TRR296, CRC1382)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (CSP 21-1)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, nuclear receptors, peroxisome proliferator-activated receptors, liver inflammation, liver fibrosis, metabolic syndrome, insulin resistance, immunometabolism, hepatocyte death, lipotoxicity, gut dysbiosis, hepatic macrophages, hepatocellular carcinoma, combination therapy
- MeSH terms
- Diabetes Mellitus, Type 2, Fibrosis, Carcinoma, Hepatocellular, Humans, Inflammation, Liver, Liver Neoplasms, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.